Silver carp muscle hydrolysate ameliorated atherosclerosis and liver injury in apoE-/- mice: the modulator effects on enterohepatic cholesterol metabolism

Atherosclerosis (AS) is a major cause of cardiovascular diseases (CVDs) and a strong link with hepatic steatosis. Silver carp muscle hydrolysate (SCH) possess various beneficial activities but its effect on AS and hepatic steatosis is yet unknown. This study aimed to investigate the effects of SCH o...

Full description

Saved in:
Bibliographic Details
Main Authors: Kai Wang, Zixin Fu, Yuqing Tan, Hui Hong, Jianping Wu, Yongkang Luo
Format: Article
Language:English
Published: Tsinghua University Press 2024-11-01
Series:Food Science and Human Wellness
Subjects:
Online Access:https://www.sciopen.com/article/10.26599/FSHW.2023.9250018
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atherosclerosis (AS) is a major cause of cardiovascular diseases (CVDs) and a strong link with hepatic steatosis. Silver carp muscle hydrolysate (SCH) possess various beneficial activities but its effect on AS and hepatic steatosis is yet unknown. This study aimed to investigate the effects of SCH on AS lesions and hepatic steatosis using apoE-/- mice. Results showed that SCH significantly reduced the vascular AS plaques and alleviated hepatic steatosis lesions in apoE-/- mice. Consistent with this, the lipid levels both in circulation and liver were lowered by SCH. The mechanism analysis showed SCH down-regulated the expression of genes involved in lipoproteins production while up-regulated the expression of genes related to reverse cholesterol transport (RCT) in liver. Meanwhile, SCH remarkably promoted transintestinal cholesterol excretion (TICE) process in intestine, partly contributing to the reduction of blood lipids. The peptide profile data indicated LYF, HWPW, FPK, and YPR are the main peptides in SCH that play a vital role in alleviating AS lesions and hepatic steatosis. Our findings provided new knowledge for the application of SCH in ameliorating CVDs and liver diseases.
ISSN:2097-0765
2213-4530